BioInfra Life Science Inc. (XKON: 266470)

Market Cap	7.02B
Revenue (ttm)	1.78B
Net Income (ttm)	-3.59B
Shares Out	21.67M
EPS (ttm)	-266.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	277
Average Volume	5,313
Open	364.00
Previous Close	322.00
Day's Range	300.00 - 364.00
52-Week Range	180.00 - 580.00
Beta	0.05
RSI	47.55
Earnings Date	n/a

About BioInfra Life Science

BIOINFRA Life Science Inc., a healthcare company, develops cancer gene treatments and technologies that monitor the possibility of metastasis and recurrence in blood for cancer patients in South Korea. Its portfolio includes cancer screening test technology, cancer biomarker research, in-vitro diagnostics medical devices, and targeted drug delivery systems for cancer treatment. The company was founded in 2001 and is based in Seoul, South Korea.

• Industry: Surgical and Medical Instruments and Apparatus
• CEO: Dukyun Lee
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 266470

Financial Performance

In 2019, BioInfra Life Science's revenue was 1.87 billion, an increase of 20.83% compared to the previous year's 1.55 billion. Losses were -3.28 billion, -13.88% less than in 2018.